Giovanni Rindone

Humoral and cellular immune response in patients with hematological disorders after two doses of BNT162b2 mRNA COVID‐19 vaccine: A single‐center prospective observational study (NCT05074706)

L. Antolini, C. Gambacorti-Passerini, R. Piazza, 2022, EJHaem.

Long term safety and efficacy of crizotinib in relapsed/refractory ALK+ lymphomas: a monocentric analysis.

R. Chiarle, C. Gambacorti-Passerini, R. Piazza, 2022, Blood advances.

DNA Damage Response (DDR) Is Associated With Treatment-free Remission in Chronic Myeloid Leukemia Patients

Mario Mauri, C. Gambacorti-Passerini, R. Piazza, 2023, HemaSphere.

A monocentric analysis of the long-term safety and efficacy of crizotinib in relapsed/refractory ALK+ lymphomas

R. Chiarle, C. Gambacorti-Passerini, R. Piazza, 2022, Blood Advances.